Table 6.
Number of RFs In Control |
Death† | Death/MI/Stroke† | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p Value | HR | 95% CI | p Value | |
0–2 | 3.8 | 2.2–6.5 | <0.0001 | 2.4 | 1.6–3.6 | <0.0001 |
3 | 2.4 | 1.4–4.1 | 0.0009 | 2.0 | 1.3–2.8 | 0.00011 |
4 | 1.9 | 1.1–3.0 | 0.0142 | 1.6 | 1.1–2.3 | 0.0163 |
5 | 1.5 | 0.9–2.4 | 0.1365 | 1.4 | 1.0–2.1 | 0.0709 |
6 | 1.0 | Reference | -- | 1.0 | Reference | -- |
Global p value | <0.0001 | 0.0005 |
RFs in-control defined as: non-HDL-C <130 mg/dl, TG <150 mg/dl, 110 mm Hg< SBP < 140 mm Hg, DBP <80 mm Hg, 6.5%< HbA1c <7.5%, nonsmoker. Note redefinition of target range for SBP and HbA1c in this exploratory analysis
Cox models adjusted for baseline number of RF in control, number of total lesions, abnormal LVEF, myocardial jeopardy index, history of prior revascularization, age, sex, race/ethnicity, country, and trial strata.